Earlier in the week, I wrote about a cancer vaccine treatment that Stanford pathologist Edgar Engleman, MD, developed in the early 90s. As expected, the FDA gave the vaccine, called Provenge, the thumbs up today; according to Dow Jones (subscription required), the agency approved Provenge for patients with advanced prostate cancer who have failed hormone therapy treatment.
Popular posts
Physician explains how COVID-19 mutes sense of smell
Physician-scientist weighs in on how the virus behind COVID-19 hampers your sense of smell and, sometimes, taste.
